As part of the “Mars Bleu” operation, which is dedicated to the early detection of colorectal cancer, researchers from the Gustave Roussy Institute announced the start of a novel clinical trial. It consists in the creation of 3D mini-tumors that will make it possible to test different available treatments in order to know which one should be administered according to the case.
Colorectal cancer is the third most common type of cancer and the second most fatal cancer, responsible for over 51,020 deaths per year. In 2018, more than 101,420 people have been diagnosed with colorectal cancer.
It develops on the walls of the colon or rectum from benign tumors called polyps. These polyps, which can occur without symptoms, can develop into cancer in a process that can take up to 10 years. If diagnosed in a localized phase, it can be treated surgically. But if it spreads and forms metastases, it can rarely be cured.
A new study carried out by researchers from the Gustave Roussy Institute aims to offer patients in this situation a customized treatment with organoids, a 3D copy of their tumors made from a sample. These have the same characteristics of the tissue (healthy or diseased, e.g. tumour) from which they originate. “To this day, chemotherapy is the reference treatment for colorectal cancer and more generally for digestive cancer. These cancers have not benefited from the two most recent therapeutic revolutions in oncology, namely immunotherapy and precision medicine,” explains Dr. David Malka, an oncologist with Gustave Roussy.
With a miniature cancer avatar
He adds: “Some patients quickly find themselves in a therapeutic impasse that is difficult to accept because they are often still able to receive other treatments. “In order to identify additional treatment options for this patient profile, the doctors at the Gustave Roussy Institute developed Organotreat-01, a clinical trial called “personalized medicine” based on organoids. “This miniature cancer avatar reproduces the cancers special features: biological properties, resistance to therapy, a reflection of the patient’s therapeutic history”, says Prof. Fanny Jaulin, who co-directs the Organotreat-01 study.
The aim of this first study is to use these 3D mini-tumors to determine the best possible treatment from a panel of drugs and then administer it to the patient. “Although organoids are now widely used in basic research, no clinical trial has yet investigated their usefulness in guiding the treatment of patients with digestive cancer,” adds Professor Fanny Jaulin. The first step of the project is to produce in the laboratory the organoids of patients with advanced colorectal, liver, biliary or pancreatic cancer from a tumor that has been non-invasively removed from the patient.